Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So

Executive Summary

Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.

You may also be interested in...



Novartis CEO Sees Recovery Ahead, Fueled By Pipeline And Alcon Growth

Novartis' half-year results show eye business Alcon and heart drug Entresto - which have been the two main sources of concern - are finally turning around, and its pipeline is firing on all cylinders towards a post-Gleevec recovery.

1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi

Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the pricing debate in the US may have lost some steam, the negative impact of pricing pressure on J&J's pharma sales have analysts concerned.

Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto

Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel